|Min SIP Amount||₹100|
|NAV||₹241.78 (27 Oct 2020)|
|Fund Started||01 Jan 2013|
|Fund Size||₹3,911 Cr|
|Aurobindo Pharma Ltd.||Healthcare||Equity||10.0%|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||9.7%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||9.6%|
|Divi's Laboratories Ltd.||Healthcare||Equity||9.3%|
|Thyrocare Technologies Ltd.||Healthcare||Equity||5.5%|
|Fortis Healthcare (India) Ltd||Healthcare||Equity||5.0%|
|Cadila Healthcare Ltd.||Healthcare||Equity||4.0%|
|Sanofi India Ltd.||Healthcare||Equity||3.9%|
Nippon India Pharma Fund Direct Growth is a Equity Mutual Fund Scheme launched by Nippon India Mutual Fund. This scheme was made available to investors on 01 Jan 2013. Sailesh Raj Bhan is the Current Fund Manager of Nippon India Pharma Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹3,911 Cr and the Latest NAV as of 27 Oct 2020 is ₹241.78.
The Nippon India Pharma Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 month.
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.